Fereshtesadat Fakhredini1,2, Esrafil Mansouri1,2, Seyyed Ali Mard3, Armita Valizadeh Gorji4, Mohammad Rashno5, Mahmoud Orazizadeh1,6. 1. Cell and Molecular Research Centre, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 2. Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 3. Department of Physiology, Physiology Research Centre, Research Institute for Infectious Diseases of the Digestive System, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 4. Department of Bone Marrow Transplantation, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 5. Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 6. Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: orazizadehm@gmail.com.
It is widely accepted that diabetic nephropathy
(DN) is one of the destructive complications of
diabetes mellitus and one of the main causes of
End-stage renal disease (ESRD) worldwide (1).
Statistically, approximately 347 million people
suffer from diabetes, and this number is estimated
to reach 430 million in 2030. DN is becoming
more common and has almost reached epidemic
proportions (1, 2). The diverse structural and
functional modifications responsible for DN
pathogenesis include hemodynamic changes,
expression or activation of different proteins and
signalling pathways, oxidative stress, mesangial
cell expansion, fibrosis development and
glomerulosclerosis (GS) (3). Despite common
treatments that include ameliorating high blood pressure and hyperglycaemia, there are no efficient
treatment options that counteract and reverse DN (4-
6). Over the past decade, cell therapy is increasingly
considered to be one of the newly developed regenerative
therapies for renal damages (7).The results of studies show that the effectiveness
of treatment on these cells is strongly associated with
exosomes, which are membrane-bound extracellular
vesicles (8). Exosomes are microvesicles that have a
two-layer lipid membrane and are secreted by different
cell types. They play an important role as an alternative
mechanism for biological transport between distant cells.
This transport is characterised by an intracellular packaging
process in which various proteins and other gene products
are loaded into exosomal carriers and then released into
the extracellular environment (9). The two lipid layers
of the exosomes protect their contents from destruction by proteases and nucleases present in the bloodstream.
Exosomes also have protein markers on their surface that
reflect their endosomal origin. They are considered to be
cell-derived vesicles, 30 to 100 nm in diameter, which are
discharged into the microenvironment via numerous cell
types (10). Exosomes consist of microRNAs (miRNAs),
proteins, and mRNAs that can be transferred to target
cells and cause epigenetic and genetic changes to the
target cells (11). Horizontal transfer of vesicular miRNAs
and mRNAs may result in an angiogenic program in
endothelial cells or modulate the injured cell phenotypes
(12).Based on the results of studies, miRNAs are considered to be one of the groups of non
coding RNAs that are expressed in all tissues. They play important roles in various
diseases, including diabetes (13). Increased glucose levels stimulate
miR-377 expression, which results in increased fibronectin production via
repression of superoxide dismutase and p21-activated kinase (14). miR-377
targets hemeoxygenase-1 (HO-1) and HO-1 prevents DN through antioxidant effects. The
miR377/ HO-1 pathway could be a new pathway where
miR-377 stimulates DN via HO-1 (15, 16). Three members of the
miR-29 family are suppressed under elevated glucose conditions in
proximal tubular cells, mesangial cells and podocytes (17). The members of the
miR-29 family are responsible for anti-fibrotic effects in DN.
miR-29a directly targets the 3′UTR of
COL4α1 and COL4α2, and leads to decreased expressions of
these two fibrotic genes (18, 19).The current study aims to evaluate the effects of
exosomes derived from kidney tubular cells (KTCs) on
DN in a rat model of diabetes. We propose that KTC-Exos
could modulate kidney complications from diabetes and
they could be a possible new regulator in DN therapy.
Materials and Methods
In this experimental study, male Sprague-Dawley rats
(n=40, 220-270 g) were obtained from the Animal House
Centre of Ahvaz Jundishapur University of the Medical
Sciences (Ahvaz, Iran). The rats were kept in cages on a
12/12-hour light/dark cycle at 21-24˚C. Ethical Committee
of Ahvaz Jundishapur University of Medical Sciences
approved this study (IR.AJUMS.ABHC.REC.1398.008).
Culture of the kidney tubularcell line
The rabbit KTC line (RK13, NCBI code: C523) was purchased from Pasteur Institute of Iran
and immediately transferred to Dulbecco’s Modified Eagle Medium (DMEM) high glucose
(Gibco, UK) that consisted of 2 mM L-glutamine and 100U penicillin/streptomycin (all from
Invitrogen, Waltham, MA, USA) and 10% fetal bovine serum (FBS, Gibco, UK). The cells were
stored in an incubator at 37˚C and 5% CO2 to enable proliferation. The medium
was replaced after five days, and the cells were washed with phosphate buffered saline
(PBS, Sigma, USA) in order to remove any non-adherent cells. The cells were passaged using
0.25 % trypsin when they were~90% confluent.
Isolation and purificationof the kidney tubular cell-derived exosomes
KTC-Exos were prepared and treated according previously published protocols (20, 21).
Briefly, the 80- 90% confluent cells were washed with PBS, and then cultured at 37˚C and
5% CO2 in DMEM without FBS for an additional 48 hours. The exosomes were
isolated from the supernatant of passage-2 cells, 48 hours after cultivation in serum-free
DMEM. The conditioned medium was collected and centrifuged at 300 g for 10 minutes, 2000 g
for 10 minutes, and 10 000 g for 30 minutesat 4˚C to remove the cells, large dead cells,
and debris. The resultant supernatant was filtered through a sterile 0.22 μm (Millipore,
USA) filter to remove any remaining cells and cellular debris. Afterwards, the supernatant
was transferred to an ultra-clear tube (Millipore, USA) and centrifuged with a high-speed
centrifuge at 60 000×g at 4˚C for 90 minutes to isolate the purified exosomes, as a final
pellet (22). The KTC-Exos pellet was resuspended in 200μl of PBS and stored at -80˚C. The
protein contents of the KTCs-Exos solution were determined by the Bradford assay,
according to the manufacturer’s instructions (Thermo Fisher Scientific, USA). Absorbance
was read at 595 nm using a microplate reader.
Transmission electron microscopy and scanning
electron microscopy of kidney tubular cell-derived
exosomes
Both transmission electron microscopy (TEM) and
scanning electron microscopy (SEM) were used to
assess the morphological features of the exosomes. First,
the exosomal pellet was fixed with 1% glutaraldehyde
(Sigma, USA) and then 20 μl of the fixed exosomes
were inserted on a carbon-coated grid and allowed to dry
at room temperature for 30 minutes. Then, a LEO 906
TEM (Zeiss, Germany) was used to each the samples
were washed twice with PBS for 5 minutes, and stained
with 1% uranyl acetate for 10 minutes before they were
visualized under a TEM at an accelerating voltage of 80
kV. DigitalMicrographsoftware (Gatan, Inc., Washington,
DC, USA) was used to record the TEM images that
were acquired with an Orius 200 camera (Gatan, Inc.,
Washington, DC, USA). We also assessed the particle
surface morphology by SEM. A total of 1 to 5 μl of the
dried sample was placed on a silicon chip, fixed with
2% paraformaldehyde and sputter-coated with gold-palladium, then visualised by SEM at 30 kV.
Determination of the distribution and size of the
kidney tubular cell-derived exosomes by dynamic
light scattering, using a Zetasizer Nano device
Dynamic light scattering (DLS) was used to analyse the
solvent nanoparticle (NP), which is capable of measuring
particles in a solution quickly, easily, and without sample
preparation. For this purpose, the extracted exosomes were resuspended in PBS (100 µl). After shaking the
solution, a Malvern Zetasizer Nano device (Malvern
Instruments, Malvern, UK) was used to measure the sizes
of the exosomes.
Western blot for characterisation of the kidney tubular
cell-derived exosomes surface markers
We used Western blotting to characterise the KTC-Exo
surface markers. The presence of two specific surface
markers, CD9 and CD63, confirmed the KTC-Exos identity
(23). Briefly, the exosomes were lysed with RIPA/PI buffer
(Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and the
level of protein was estimated by the Bradford protein assay.
Then, the KTC-Exos protein was loaded onto a 12% sodium
dodecyl sulphate/poly-acrylamide gel electrophoresis (SDS-PAGE). In addition, the protein samples were transferred to
the polyvinylidenedifluoride membrane via electroblotting
the membrane of polyvinylidenedifluoride (Millipore, USA)
at 100 mA for 1.5 hours. Then, themembranes were exposed
to the primary rabbit polyclonal anti-CD9 and anti-CD63
antibodies, and the β-actin antibody (Abcam, UK) in order
to test for the presence of CD63 and CD9. The membranes
were washed three times for 5 minutes each time in 1× tris-HCl buffered saline with Tween (TBST) that consisted of
TBS and 0.1% Tween 20. Incubation was done in TBST
with the horseradish peroxidase-conjugated goat anti-rabbit
secondary antibody (Abcam, UK) for one hour. ECL solution
was applied for detection and imaging of the proteins in the
membrane. Lumigan PS-3 substrate is catalyzed in ECL
solution by a horseradish peroxidase enzyme connected to the
secondary antibody. The radiation produced by luminol was
released as a result of this reaction and was detected using
special films. The protein bands that resulted were compared
between groups and statistically analyzed.
Assay of KTC-Exos -Exo by atomic force microscopy
The exosomal pellet was prepared over several rounds
of high-speed centrifugation, and then diluted in 5 ml of
deionized water and vortexed. The exosomal solution was
subsequently transferred to the south-central laboratory
of Ahvaz Jundishapur University of Medical Sciences.
Distribution, size, NP size, characteristics, morphology,
and surface features of the soluble exosomes were
analysed by atomic force microscopy (AFM). The two-dimensional images were also analysed.
Diabetes induction
The healthy male rats were allowed to fast for 24 hours
before diabetes induction. A single intraperitoneal (i.p.)
injection of streptozotocin (STZ, 50 mg/kg body weight,
Sigma, USA) (24) that was recently dissolved in citrate buffer
(0.1 M at pH=4.5) was used to induce diabetes. The control
animals were injected with the vehicle buffer. Blood samples
were obtained from the animals’ tail veins 72 hours after the
STZ injection. Fasting blood glucose levels were measured
by a glucose strip test and a glucometer (EasyGlucoBlood
Glucose Monitoring System, Infopia, South Korea). Animals
with fasting blood glucose levels<250 mg/dl were considered to have diabetes (24).
Experimental design
A total of 40 animals were selected and placed into four
groups (n=10 per group). Group 1 was the control group
that injected via the tail veins for six weeks. Group 2
(sham group) received 100 μg of an exosome solution in
100 μl of PBS that was injected through the tail veins once
per day for six weeks. Group 3 comprised the diabetes
group, where rat received a single i.p. injection of STZ
(50 mg/kg). Group 4 was the diabetes+KTC-Exos group
that received 100 μg of the exosome solution in 100 μl
of PBS by injection (25, 26) into the tail veins once per
day for six weeks. The animals were separately placed
in metabolic cages for 24 hours with access to drinking
water in order to measure the 24-hour urine total protein
levels upon the completion of the experiment.
Measurement of 24-hour urine protein, blood urea
nitrogen and serum creatinine levels
A Bicinchoninic acid (BCA) kit was used to measure urine that was collected following the
6th week of exosome treatment. A combination ofthe urine and BCA working
solution was incubated at 37˚C for 30 minutes, and optical density (OD) was examined at a
wavelength of 562 nm. At the end of experimental period, the rats were sacrificed after
administration of chloral hydrate anaesthesia. Blood plasma was collected from left
ventricles of the rats and centrifuged at 3500 rpm for 5 minutes. Both the serum
creatinine (Scr) and blood urea nitrogen (BUN) levels were measured by kits (Scr, C011-1,
BUN, C013-2, both purchased from Jiangcheng Bio, Nanjing, China). Then, the kidneys were
removed. The left kidneys were washed by PBS and fixed with 10% buffered formalin for
sectioning into paraffin sections followed by periodic acid-Schiff (PAS) staining. The
right kidneys were rinsed, snap-frozen in liquid nitrogen and stored at -80˚C for the
miR-29a and miR-377 assays.
Light microscopy examination
We observed the PAS stained sections under a light
microscope. Summarily, the mesangial area was counted
as mesangial expansion, which was determined in 20
consecutive glomeruli from each rat (26). Finally, the
relative mesangial expansion was characterised as the
fold change from the normal controls.
Extraction of microRNAs and cDNA synthesis
AnmiRNeasy/Plasma kit (Roche, cat. no.: 05080576001,
Germany) was used according to the manufacturer’s
instructions to extract the miRNAs from the frozen
specimens. A spectrophotometer at 260 nm and 280
nm wavelengths (NanoDrop Thermo Fisher Scientific,
S.N:D015) was utilized to determine the RNA purity and
concentration. Subsequently, cDNA was synthesized from
1 μg of total RNA using amiScript II RT Kit (BONmiR,
BON209001, Iran) based on the company’s instructions.
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (qRT-PCR) with a light cycler 96 RT-PCR
system (Roche Diagnostics, Indianapolis, IN, USA) was used to measure miRNA expressions.
Each PCR amplification was performed in duplicate and the resultant volume of 13 µL that
consisted of 6.5 µL 2x QuantiTect SYBR Green PCR Master Mix, 1 µL cDNA, 4.5 µL RNAase-free
water, and 0.5 µL miRNA-specific forward Primer (miR-29a [ACT GAT TTC TTT TGG TGT] or
miR-377 [CGA TCA CAC AAA GGC A]; Bonyakhteh), and 0.5 µL universal reverse primer ([ACT
TAT GTT TTT GCC GTT T] Bonyakhteh). The initial activation phase was conducted at 95˚C for
two minutes to activate the HotStarTaq DNA polymerase and then for 40 cycles at 95˚C for 5
seconds and 60˚C for 30 seconds. Additionally, the non-template control (H2 O)
was regularly in each PCR. RNU87, as the internal control, was used to normalize miRNA
expression levels and the fold change was computed with 2-ΔΔCt. Each sample was
assayed three times.
Statistical analysis
Statistical analysis was carried out with SPSS 16
software (SPSS Inc., USA). The data were analysed using
one-way ANOVA followed by post hoc Least Significant
Difference (LSD) test and are presented as mean ± SD.
P<0.05 was considered significant.
Results
Kidney tubular cell phenotype
We observed the KTCs in the cell culture flasks every day
after the first day of culture. The morphology and growth of
these KTCs were checked by light microscopy to verify an
epithelial-like morphology and growth rate. The epithelial-like cells showed high rapid growth and were approximately
95% confluent after 3-4 days (Fig .1).
Fig.1
Morphology and growth of kidney tubular cells (KTCs). Growth cells after A. Two days
and B. Four days at ×100 magnification (scale bar: 100 µm).
Morphology and growth of kidney tubular cells (KTCs). Growth cells after A. Two days
and B. Four days at ×100 magnification (scale bar: 100 µm).
Transmission electron microscopy evaluation of the
exosomes
The exosomes generated by the KTCs were separated
from the culture medium by different centrifuge speeds and
evaluated by TEM (Fig .2). Ultrastructural analyses of the
exosomes showed considerable reinforcement of the typical spherical-shaped exosomes with diameters of 50-150 nm. In
addition, TEM evaluations showed that the exosomes had an
average diameter of≤150 nm with an intact round morphology
and they possessed membranes (Fig .2A).
Fig.2
Characterization of exosomes. A. Transmission electron microscopy (TEM) observations
indicated that the average diameter of the exosomes was ≤150 nm. The exosomes had a
preserved intact spherical morphology. B. Scanning electron microscopy
(SEM) analysis showed that the average diameter of the exosomes was ≤100 nm and they
had a preserved intact spherical morphology. C. Dynamic light scattering
(DLS) results indicated that almost 50% of the solution ingredients had an average
diameter of 99.4 nm.
Determination of the exosome protein concentration
by the Bradford method
The protein concentration of the isolated exosomes was
calculated by the Bradford methodand BSA was used as
the standard. The protein concentration in the sample was
2512 μg/ml.
Scanning electron microscopy evaluation of the
exosomes
SEM was used to assess the outer surface characteristics
of the exosomes. Small vesicles with round morphology
were observed. The size of the vesicles was determined to
be 70-260 nm based on the vesicle sizes that were seen in
several images. The majority of the vesicles were smaller
than 100 nm in size (Fig .2B).
Dynamic light scattering analysis
DLS analysis of the exosomes size showed a bell-shaped
size distribution with a peak at about 99.4 nm (Fig .2C).Characterization of exosomes. A. Transmission electron microscopy (TEM) observations
indicated that the average diameter of the exosomes was ≤150 nm. The exosomes had a
preserved intact spherical morphology. B. Scanning electron microscopy
(SEM) analysis showed that the average diameter of the exosomes was ≤100 nm and they
had a preserved intact spherical morphology. C. Dynamic light scattering
(DLS) results indicated that almost 50% of the solution ingredients had an average
diameter of 99.4 nm.
Western blot analysis
The results of Western blot analysis showed the expressions
of two exosome markers, CD63 (25KDa) and CD9 (24-27
KDa), in the KTC-Exos (Fig .3). β-actin (42 KDa) was used as
the positive control. Both expression patterns were significant
and the results confirmed that the NPs were exosomes.
Fig.3
Expression of exosome surface markers by western blotting. A. The exosome markers
CD9 (24-27 KDa) and CD63 (25 KDa) were expressed in the kidney tubular
cell-derivedexosomes (KTC-Exos). β-actin (42 KDa) was used as the positive control.
B. Atomic force microscopy (AFM) image of the KTC-Exos. This showed
distinct spherical particlesthat ranged from 60 to 150 nm.
Expression of exosome surface markers by western blotting. A. The exosome markers
CD9 (24-27 KDa) and CD63 (25 KDa) were expressed in the kidney tubular
cell-derivedexosomes (KTC-Exos). β-actin (42 KDa) was used as the positive control.
B. Atomic force microscopy (AFM) image of the KTC-Exos. This showed
distinct spherical particlesthat ranged from 60 to 150 nm.
Atomic force microscopy analysis
AFM obtained from the exosomes showed that the NPs
were symmetric, spherical, and without aggregation. The
size of the NPs ranged from 60 to 150 nm (Fig .3).
Urine volume in diabetic rats after injection of kidney
tubular cell-derived exosomes
Intravenous injection of the KTC-Exos significantly
decreased polyuria in the diabetic rats compared with the
diabetic group (P<0.001, Fig .4A).
Fig.4
Effects of the kidney tubular cell-derived exosomes (KTC-Exos) on rats with diabetes.
A. Urine volume, B. 24-hour urine protein, C.
Serum creatinine (Scr), and D. Blood urea nitrogen (BUN) levels in the
control and diabetes groups before and after treatment with KTC-Exos. Values are
expressed asmean ± SD for eight rats. ***; P<0.0001 (comparison with control),
#; P<0.01, ##; P<0.001, and ###; P<0.0001 (comparison with
diabetes).
Biochemical analysis
The results showed remarkably elevated Scr, BUN and 24-
hour urine protein levels in the diabetic group in comparison
to the control group. The KTC-Exos group had significant
decreases in Scr (P<0.01), BUN (P<0.001), and 24-hour
urine protein (P<0.0001) levels (Fig .4B-D).
Periodic acid-Schiff staining
At the end of the 6th week following the creation of the diabetes model, we
observed focal mesangial matrix expansion in the diabetic animals in comparison with the
control group (Fig .5A1). Moreover, the section obtained from the diabetic group’s kidneys
demonstrated partial glomerular hypertrophy and enhanced intra-glomerular cells that were
located mainly in the mesangial region with mesangial expansion (Fig .5BI). In the diabetic
animals that received KTC-Exos, there was enhancement in intraglomerular cells and the
mesangial matrix. No obvious sign of the rapid growth of the mesangial matrix and
glomerular hypertrophy were observed (Fig .5CI). According to quantitative analyses, the
KTC-Exos Significantly prevented mesangial expansion the mesangial expansion
(P<0.0001, Fig .5II).
Fig.5
Intravenous injection of the kidney tubular cell-derived exosomes (KTC-Exos) ameliorated the
changes in renal histopathology in diabetic rats after six weeks. 1.
Light microscopy examination of tissue sections that were stained by periodic
acid-Schiff (PAS) from the different groups. A. Control, B.
Diabetic, C. Diabetes treated with KTC-Exos, and D.
Sham groups.2. Quantitative analysis of mean mesangial area from each
group of rats. The results are expressed as the means ± standard deviation for eight
rats. ***; P<0.0001, versus control group, ###; P<0.0001, versus
diabetic group, and GS; Glomerulosclerosis (magnification: x400).
Effects of the kidney tubular cell-derived exosomes (KTC-Exos) on rats with diabetes.
A. Urine volume, B. 24-hour urine protein, C.
Serum creatinine (Scr), and D. Blood urea nitrogen (BUN) levels in the
control and diabetes groups before and after treatment with KTC-Exos. Values are
expressed asmean ± SD for eight rats. ***; P<0.0001 (comparison with control),
#; P<0.01, ##; P<0.001, and ###; P<0.0001 (comparison with
diabetes).Intravenous injection of the kidney tubular cell-derived exosomes (KTC-Exos) ameliorated the
changes in renal histopathology in diabetic rats after six weeks. 1.
Light microscopy examination of tissue sections that were stained by periodic
acid-Schiff (PAS) from the different groups. A. Control, B.
Diabetic, C. Diabetes treated with KTC-Exos, and D.
Sham groups.2. Quantitative analysis of mean mesangial area from each
group of rats. The results are expressed as the means ± standard deviation for eight
rats. ***; P<0.0001, versus control group, ###; P<0.0001, versus
diabetic group, and GS; Glomerulosclerosis (magnification: x400).
Effect of kidney tubular cell-derived exosomes on
expression levels of miR-377 and miR-29a
As seen in Figure 6, the qRT-PCR results show that miR-377 expression
considerably increased, where as miR-29a expression significantly
decreased following DN. In the KTC-Exos group, the level of increased
miR-377 significantly decreased (P<0.001) and
miR-29a expression significantly (P<0.001). The levels of
miR-377 and miR-29a in the sham group were similar to
the control group.The effect of kidney tubular cell-derived exosomes (KTC-Exos) on the expression levels of
A. miR-377 and B.
miR-29a following diabetic nephropathy (DN) injury. The quantitative
real-time polymerase chain reaction (qRT-PCR) results showed that
miR-377 expression was significantly increased (P<0.01)
whereas miR-29a expression significantly decreased (P<0.01) in
the DN rats. The expression level of miR-377 in the Dia+Exo Rats was
significantly lower compared to the diabetes group, and the expression level of
miR-29a in Dia+Exo Rats was significantly higher than the diabetes
group. Data are presented as the means ± standard deviation for eight rats. *;
P<0.01 versus the control group and ##; P<0.001 versus the diabetes
group.
Discussion
This study was designed to assess exosomes derived
from highly differentiated KTCs as treatment for DN. DN
is one of the main causes of ESRD and it is characterised
by pathological modifications to the kidneys, which
results in progressive loss of glomerular filtration rate,
tubule-interstitial fibrosis, and proteinuria. Current
treatments include precise monitoring of blood pressure
and glucose levels, as well as blockage of the rennin-angiotensin mechanism in order to stop DN progression
(27). However, novel treatment options for DM should
be devised by experts in this field. Notably, several
parameters could influence DN expansion after the onset
of proteinuria (28).The present study focused on the main factors involved
in DN - endothelial cells and podocytes, both of which
have tremendous contributions to the creation of filtration
barriers. Increased glucose may decrease density and the
numbers of podocytes, eliminate integrity of glomerular
filtration membranes, modify its selective permeability,
and enhance the development of glomerular sclerosis that
can increase DN. Both loss and injury of the interacting
proteins of the podocytes can promote apoptosis and
destroy slit membrane integrity, thereby aggravating
proteinuria and accelerating development of DN (29).The potential use for exosomes in various research and clinical practices has made it one of the probable therapeutic
options for improving DN. In comparison to stem cells,
KTCs also have advantages, especially in regenerative
medicine. Some important studies have focused on
the effects of exogenous kidney-derived exosomes on
renal failure, such as ischemia-reperfusion (30). It is
hypothesized that differentiated kidney cells may present
more advanced developmental and cell differentiation
impacts in comparison with undifferentiated cells; the
contents of their exosomes may be different and more
effective in treating renal injuries.We isolated the exosomes by performing sequential and differential centrifugation
procedures, as a general strategy, which resulted in the successful generation of KTC-Exos.
Next, we assessed the ability of these KTC-Exos to control or reverse DN. The rats that
received the KTC-Exos showed significant suppression of polyuria, proteinuria, Scr, and BUN
expression levels. One of the main purposes of the present study was to evaluate the impact
of KTC-Exos on miR-29a and miR-377 expression in DN
progression and pathogenesis in diabetic rats. We observed a considerable increase in mean
miR-377 expression and a significant decrease in mean
miR-29a expression in the DN animals compared to the control group. This
study showed that KTC-Exos administration led to significant downregulation of
miR-377 and upregulation of miR-29a in kidney cells of
the treated rats. These results suggested that KTC-Exos had a protective function in high
glucose-induced miRNA and growth factors (31).miRNA dysregulations have been identified in many
research areas, including DN (32). miRNAs are pivotal
regulators of cellular and molecular pathways; therefore,
identifying the targets of DN-associated miRNAs can
provide further insights into the pathogenesis of DN (33).In addition, miRNAs in extracellular environments are
the essential modulators in renal fibrosis, DN, progressive
kidney diseases, and acute kidney injuries. The miRNAs
packed in extracellular vesicles, like exosomes, have
shown modifications in concentrations related to the
incidence of DN and are considered to be potent non-invasive biomarkers that can be used to diagnose and treat
DN in patients (34).There was high expression of miR-377 in the increased glucose-treated
cultured cells, Transforming growth factor beta (TGF-β) treated humans, and
mice mesangial cells. Increased expression of miR-377 led to suppression of
p21-activated kinases and superoxide dismutase, which promoted
fibronectin expression. The results of previous studies have shown that
miR-377 caused a decrease in the activities of some target genes,
PAK1 and SOD1/2. This led to increased vulnerability to
the oxidant stresses and fibronectin accumulation in the extracellular matrix (ECM) (35).
Therefore, this miRNA could pivotally contribute to the response of the mesangial cells to
diabetic medium and may be a target miRNA for therapy.Other miRNAs, such as the miR-29 family (miR-29a, miR-29b,
miR-29c), are responsible for anti-fibrotic effects in DN.
miR-29a directly targets the 3′UTR of COL4α1 and
COL4α2, leading to decreased expressions of these two fibrotic genes
(36). The miR-29 family targets a group of mRNAs that encode the proteins
implicated in fibrosis, as numerous collagens, elastin and fibrillin. Consequently,
decreased miR-29 expression activates such mRNAs expressions and promotes
fibrotic responses (37). In cultured human proximal tubular epithelial cells, increased
glucose and TGF-β1 decrease miR-29a expression. Collagen
IV is reported to be a target of miR-29a, and miR-29a regulates collagen
expression. Decreased miR-29a levels in diabetes may increase collagen
deposition, thus mediating the DN pathogenesis (38).Recent studies have focused on exosomes as treatments
for chronic disease models. Exosomes provide protection
against the development of chronic kidney damage via
suppression of GS, tubulointerstitial fibrosis and capillary
rarefaction. For example, researchers examined exosomes
with six months following an ischaemia-reperfusion injury
(IRI) kidney model and reported that renal microvascular
density rarefaction in the presence of sustained hypoxia
had a correlation with acceleration of development
towards chronic kidney diseases. Microvesicles can reduce
tubule-interstitial fibrosis, microvascular rarefaction, and
GS, which maintain renal functions (39). Furthermore,
the obtained histopathological results showed the ability
of exosomes decrease kidney damage, including GS, in a
diabetic model.Based on the literature and the present study results,
exosomes extracted from the KTCs may prevent
kidney impairments in diabetic patients. Therefore,
the combination of exosomes and KTCs would be an
encouraging treatment approach in regenerative medicine
that would have less immune rejection, increased stability
and more acceptable differentiation.
Conclusion
The present findings showed that exosomes derived from KTCs can ameliorate kidney damages
in animals with diabetes. Several miRNAs are involved in the pathogenesis and development of
DN, where as other miRNAs prevent this disease. Restoration of miRNAs expression to a normal
level may be a therapeutic potential for stopping or attenuating disease progression. We
have shown that administration of KTC-Exos resulted in upregulation of
miR-377 and downregulation of miR-29a in DN, and significantly modulated
and improved the symptoms of this disease. These miRNAs present a notable capacity for
acting as biomarkers for diagnosing, treating, and prognosis of DN. One of the newly
developed treatment approaches would be to apply KTC-Exos for treatment of DN. The effects
of exosomes on abnormal regression, damage to podocyte cells, and thickening of the
glomerular basement membrane, which are complications of DN, should be taken into
consideration in future studies.